Novozymes Biopharma’s Hyasis increases drug release of tramadol hydrochloride from 1.9 to 7.5 hours

Novozymes Biopharma’s Hyasis® increases drug release of tramadol hydrochloride from 1.9 to 7.5 hours
New findings on controlled and sustained drug release to be presented at Controlled Release Society annual meeting to address “Emerging Challenges for Global Delivery”
NOTTINGHAM, UK – 18th July 2013 –  Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
The investigation concluded that by adding Hyasis®, the Bacillus-derived Hyaluronic Acid (HA) used in the study formulated by Novozymes Biopharma, into a tablet containing tramadol hydrochloride for oral administration, the release of tramadol hydrochloride can be prolonged from 1.9 to 7.5 hours. A good correlation has been identified between the added amounts of HA and the drug release time, and this correlation gives excellent possibilities for developing specific drug release profiles for different oral drug applications.
“These results represent another step forward in meeting the emerging challenges in drug development, and we are delighted to be presenting our latest findings at the CRS annual meeting,” says Hans Ole Klingenberg, Global Marketing Director, Novozymes Biopharma. “We are committed to developing compliant formulation solutions that ensure improved stability, solubility and half-life of therapeutics and we are delighted to demonstrate how these innovative products can streamline the drug development process.”
Experimentally, the drug release was assessed by dissolution analysis using a closed loop system configuration (SOTAX CE7smart) and USP 4 dissolution method with 22.4mm dissolution cells. The tramadol was detected on-line with UV absorbance at 270nm.
Novozymes Biopharma’s Hyasis® is an ultra-pure material with exceptionally low amounts of nucleic acids, proteins, bacterial endotoxins and microbial contamination. With a reproducible molecular weight and narrow size distribution, it is well-tolerated, safe and biocompatible, allowing the sustained and controlled release of drugs in a HA concentration dependent manner.
For further information on Novozymes’ range of innovative drug delivery products or to request a copy of the scientific poster, please visit booth 416 at the 2013 CRS meeting or www.biopharma.novozymes.com
###
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at www.novozymes.com.
 
Contact:                                                           
Novozymes Biopharma:          
Sally Vernon, Global Communications Manager
Email: SYKE@novozymes.com>
Tel. +44 115 955 3355
 
MEDIA CONTACTS         INVESTOR CONTACTS
 
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com
     US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com
     
China
Zhu Xiaoqing
Office: +86 106 298 7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com
Brazil
Ana Cecilia Amarante de Oliveira
Office: +55 41 3641 1096
Mobile: +55 41 9619 7594
aaov@novozymes.com
     US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com
 

Contact: David Bertram (The Scott Partnership)
Tel: 01477 539 539 Email: novozymes@scottpr.com

 

Posted: July 2013

View comments

Hide
(web3)